Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
53.51
-0.50 (-0.93%)
Jul 23, 2026, 9:30 AM EDT - Market open
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 1,402 employees as of December 31, 2025. The number of employees increased by 333 or 31.15% compared to the previous year.
Employees
1,402
Change (1Y)
333
Growth (1Y)
31.15%
Revenue / Employee
$754,772
Profits / Employee
-$233,222
Market Cap
8.84B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,402 | 333 | 31.15% |
| Dec 31, 2024 | 1,069 | 142 | 15.32% |
| Dec 31, 2023 | 927 | 131 | 16.46% |
| Dec 31, 2022 | 796 | 136 | 20.61% |
| Dec 31, 2021 | 660 | -97 | -12.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ImmunityBio | 691 |
| Crinetics Pharmaceuticals | 594 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| TG Therapeutics | 399 |
| Immunovant | 315 |
| Krystal Biotech | 295 |
| Kymera Therapeutics | 253 |
IONS News
- 2 days ago - Ionis Pharmaceuticals price target lowered to $89 from $106 at Guggenheim - TheFly
- 7 days ago - Wolfe cuts Ionis Pharma to Peer Perform after disappointing trial data - TheFly
- 7 days ago - Ionis Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research - TheFly
- 7 days ago - Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS - GlobeNewsWire
- 8 days ago - Ionis to hold second quarter 2026 financial results webcast - Business Wire
- 9 days ago - Ionis says Biogen presents Phase 2 CELIA data at AAIC - TheFly
- 9 days ago - Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease - Business Wire
- 9 days ago - Alnylam price target raised to $485 from $470 at H.C. Wainwright - TheFly